Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases.
antifungal agents
fungal diseases
granulocyte-macrophage colony-stimulating factor
immune modulation
sargramostim
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
02
08
2022
accepted:
07
10
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Sargramostim (yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) augments innate and adaptive immune responses and accelerates hematopoietic recovery of chemotherapy-induced neutropenia. However, considerably less is known about its efficacy as adjunctive immunotherapy against invasive fungal diseases (IFDs). The clinical courses of 15 patients with pediatric malignancies and IFDs treated adjunctively with sargramostim at a single institution were analyzed in a retrospective cohort review. Further, a systematic review of published reports of rhu GM-CSF for IFDs was also conducted. Among 65 cases, 15 were newly described pediatric patients and 50 were previously published cases of IFDs treated with rhu GM-CSF. Among the newly reported pediatric patients, IFDs were caused by Sargramostim may be a potential adjunctive immunomodulator for selected patients with hematological malignancies and refractory IFDs.
Sections du résumé
Background
UNASSIGNED
Sargramostim (yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) augments innate and adaptive immune responses and accelerates hematopoietic recovery of chemotherapy-induced neutropenia. However, considerably less is known about its efficacy as adjunctive immunotherapy against invasive fungal diseases (IFDs).
Methods
UNASSIGNED
The clinical courses of 15 patients with pediatric malignancies and IFDs treated adjunctively with sargramostim at a single institution were analyzed in a retrospective cohort review. Further, a systematic review of published reports of rhu GM-CSF for IFDs was also conducted.
Results
UNASSIGNED
Among 65 cases, 15 were newly described pediatric patients and 50 were previously published cases of IFDs treated with rhu GM-CSF. Among the newly reported pediatric patients, IFDs were caused by
Conclusions
UNASSIGNED
Sargramostim may be a potential adjunctive immunomodulator for selected patients with hematological malignancies and refractory IFDs.
Identifiants
pubmed: 36381625
doi: 10.1093/ofid/ofac535
pii: ofac535
pmc: PMC9645583
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac535Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C.R. and L.L. are employees of and hold stock options for Partner Therapeutics, Inc. T.W. has received grants for experimental and clinical antimicrobial pharmacology, therapeutics, and diagnostics to his institutions from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, Shionogi, T2 Biosystems, Tetraphase, and Viosera. He has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Karyopharm Therapeutics, Leadiant, Medicines Company, Merck, Methylgene, Partner Therapeutics, Inc., Pfizer, Scynexis, Shionogi, and T2 Biosystems. C.B.S. has received grant support from GlaxoSmithKline, ViiV, Abbott, Merck, Gilead, Chimerix, Shire/Takeda, Schering-Plough, Ablynx, Janssen, Ansun Biopharma, and Karyopharm Therapeutics. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Leuk Lymphoma. 2001 Sep-Oct;42(5):1119-23
pubmed: 11697631
Mycoses. 2014 Dec;57 Suppl 3:40-7
pubmed: 25175306
Infez Med. 2004 Dec;12(4):278-83
pubmed: 15729020
Thorax. 1999 Nov;54(11):1047-9
pubmed: 10525567
J Allergy Clin Immunol. 2016 Apr;137(4):1178-1188.e7
pubmed: 26521038
Am J Respir Crit Care Med. 2011 Jul 15;184(2):259-68
pubmed: 21474645
Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):781-3
pubmed: 9923519
Leuk Lymphoma. 2001 Nov-Dec;42(6):1393-9
pubmed: 11911424
Science. 1994 Apr 29;264(5159):713-6
pubmed: 8171324
Ann Hematol. 1996 Jul;73(1):33-4
pubmed: 8695721
Curr Opin Infect Dis. 2011 Dec;24(6):527-33
pubmed: 22025021
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
J Infect Dis. 1998 Aug;178(2):589-92
pubmed: 9697751
Blut. 1990 Apr;60(4):242-8
pubmed: 2337685
J Clin Microbiol. 1995 Jan;33(1):126-30
pubmed: 7535310
Ann Hematol. 1992 Nov;65(5):232-5
pubmed: 1457582
Braz J Infect Dis. 1997 Apr;1(2):68-76
pubmed: 11107242
BMJ Case Rep. 2019 Dec 10;12(12):
pubmed: 31826901
Blood. 1980 Dec;56(6):947-58
pubmed: 7002232
J Immunol. 2000 Mar 1;164(5):2602-9
pubmed: 10679099
Scand J Infect Dis. 2001;33(10):784-6
pubmed: 11728053
J Med Microbiol. 1998 Apr;47(4):359-63
pubmed: 9569003
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5592-6
pubmed: 8202532
Mitochondrion. 2022 Jan;62:85-101
pubmed: 34740864
Case Rep Dermatol. 2020 Oct 8;12(3):168-173
pubmed: 33173476
Med Mycol. 2001 Dec;39(6):509-15
pubmed: 11798056
J Med Microbiol. 1997 Apr;46(4):321-5
pubmed: 9128196
Blood. 1991 Jul 15;78(2):533-4
pubmed: 2070090
J Infect. 2000 Jul;41(1):97-100
pubmed: 11041713
Med Mycol Case Rep. 2016 Apr 26;11:40-3
pubmed: 27182483
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Immunity. 2001 Oct;15(4):557-67
pubmed: 11672538
J Infect Dis. 1994 Oct;170(4):894-9
pubmed: 7930733
J Med Vet Mycol. 1996 Jan-Feb;34(1):63-9
pubmed: 8786473
Clin Infect Dis. 2014 Jul 1;59(1):81-4
pubmed: 24704721
Clin Infect Dis. 2001 Jun 15;32(12):e145-50
pubmed: 11360225
Blood. 1995 Jul 15;86(2):457-62
pubmed: 7605984
Haematologica. 1990 Sep-Oct;75(5):480-1
pubmed: 2097267
J Infect Dis. 2003 Feb 15;187(4):705-9
pubmed: 12599092
Mycoses. 2001 Nov;44(9-10):415-8
pubmed: 11766109
Pediatr Hematol Oncol. 1997 Sep-Oct;14(5):469-74
pubmed: 9267880
J La State Med Soc. 2002 Mar-Apr;154(2):82-5
pubmed: 12014459
Infection. 2008 Aug;36(4):368-73
pubmed: 18642108
J Interferon Cytokine Res. 2015 Aug;35(8):585-99
pubmed: 25803788
J Infect Dis. 2016 Apr 15;213(8):1289-98
pubmed: 26908736
Med Mycol. 2005 May;43(3):253-60
pubmed: 16010852
Ann Intern Med. 1990 Jun 15;112(12):966-7
pubmed: 2187396
Pediatr Diabetes. 2005 Dec;6(4):234-8
pubmed: 16390393
Med Mycol. 2017 Jan 1;55(1):109-117
pubmed: 27838641
J Allergy Clin Immunol. 2018 Oct;142(4):1334-1338.e5
pubmed: 29890237
J Pediatr Hematol Oncol. 2018 Oct;40(7):e446-e449
pubmed: 28991126
Clin Immunol. 2020 Jan;210:108292
pubmed: 31676420
Pediatr Infect Dis J. 2004 Aug;23(8):769-73
pubmed: 15295229
Int J STD AIDS. 1997 Jun;8(6):406-8
pubmed: 9179655
J Clin Invest. 1999 Feb;103(4):563-9
pubmed: 10021465
Clin Infect Dis. 1998 Jan;26(1):239-40
pubmed: 9455573
Clin Infect Dis. 1993 Apr;16(4):528-30
pubmed: 8513060
Med Mycol. 2000 Apr;38(2):161-8
pubmed: 10817233
J Leukoc Biol. 2001 Dec;70(6):868-72
pubmed: 11739548
Blood. 2009 Aug 13;114(7):1289-98
pubmed: 19436055
Fungal Genet Biol. 2009 Jun-Jul;46(6-7):496-505
pubmed: 19285564
Support Care Cancer. 1997 Jul;5(4):289-98
pubmed: 9257425
J Infect Dis. 1994 Dec;170(6):1557-65
pubmed: 7995996
Curr Ther Res Clin Exp. 2003 Jul;64(7):473-83
pubmed: 24944397
Clin Lab Haematol. 2000 Feb;22(1):41-4
pubmed: 10762303
J Med Microbiol. 2002 Jan;51(1):70-75
pubmed: 11800475
J Infect Dis. 1990 May;161(5):999-1005
pubmed: 2157774
Am J Physiol Gastrointest Liver Physiol. 2014 Mar;306(6):G455-65
pubmed: 24503766
Pediatr Infect Dis J. 2015 May;34(5):542-3
pubmed: 25420158
Cancer. 2005 Jul 1;104(1):199-204
pubmed: 15929126
Infez Med. 2004 Sep;12(3):197-204
pubmed: 15711134
Leuk Lymphoma. 2008 Jan;49(1):163-5
pubmed: 18203028
J Immunol. 2017 Feb 15;198(4):1387-1394
pubmed: 28167649
J Infect Dis. 2006 Apr 1;193(7):1023-8
pubmed: 16518765
Am J Health Syst Pharm. 2002 Apr 1;59(7 Suppl 2):S6-12
pubmed: 11944613
Front Pharmacol. 2022 Jan 17;12:735443
pubmed: 35111042
Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281(5):L1210-8
pubmed: 11597913